Corporate | 28 October 2010 07:00
Cytos Biotechnology AG / Key word(s): Quarter Results
28.10.2010 07:00
Publication of a media release
---------------------------------------------------------------------------
Cytos Biotechnology Ltd Third Quarter Report 2010 as of September 30, 2010
Summary of important events in Q3 2010
- Cytos Biotechnology presented novel Toll-like receptor 9 agonist
CYT003-QbG10 for the treatment of allergic asthma at the 2010 Annual
Conference of the European Respiratory Society
- Cytos Biotechnology establishes strong patent position around core
technology for CYT003-QbG10 in the treatment of allergic asthma and
rhinitis
- A*STAR and Cytos Biotechnology establish influenza vaccine
collaboration
- Upcoming events:
- Presentation at Next Generation Dengue Vaccines and Diagnostics
Conference, November 1/2, 2010 in Atlanta, USA
- Presentation at New Vaccines for Global Health Meeting, November 15/16,
2010 in London, UK
- Financial summary
in CHF million YTD* 10 YTD* 09 Q3 10 Q3 09
Revenue 21.7 8.4 0.3 1.8
Net operating costs (20.2) (29.6) (5.8) (7.2)
Net income/(loss) 5.2 (23.6) (6.0) (5.6)
09/30/10 12/31/09
Cash, cash equivalents, 53.2 60.5
financial assets
and trade receivables
Nominal value of the convertible 41.1 57.1
bonds not held by
Cytos Biotechnology Ltd
Full-time equivalents (number) 79 85
* YTD = year to date January 1 -
September 30
The complete Third Quarter Report 2010 can be downloaded on Cytos
Biotechnology's website under the following link:
http://www.cytos.com/userfiles/file/Cytos_Q3_2010_E.pdf
Harry Welten, MBA
Chief Financial Officer
Cytos Biotechnology Ltd
Wagistrasse 25, Postfach
CH-8952 Schlieren (Zurich)
Tel. +41 44 733 46 46
e-mail: harry.welten@cytos.com
www.cytos.com
28.10.2010 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the capital
market and press releases.
The EquityStory Group distributes authentic and real-time financial news
for over 1'300 listed companies.
The Swiss news archive can be found at www.equitystory.ch/news
---------------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in München, Berlin, Stuttgart; Open
Market in Frankfurt; Foreign Exchange(s) SIX
End of Announcement EquityStory News-Service
---------------------------------------------------------------------------